Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imdusiran (AB-729) plus Durvalumab in Chronic HBV Infection
2023-509573-23-00Phase 2Completed
- Sponsor
- Arbutus Biopharma Corporation
- Start
- Jun 2024
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Gene Therapies, Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 9
01
Overview
Phase 2, open-label, single-arm trial of imdusiran and durvalumab in Chronic Hepatitis B (CHB), sponsored by Arbutus Biopharma Corporation. Primary endpoints: Treatment-emergent adverse events and immune-related adverse events, Laboratory abnormalities by cohort and 1 more. Started Jun 2024; status: completed.
02
Drugs
imdusirandurvalumab
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on 2023-509573-23-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509573-23-00.